This is the second recall of Sandimmune related to the formulation of crystals in some bottles.
Crystal formation observed in some bottles has led Novartis to recall two lots of Sandimmune Oral Solution (cyclosporine), 100 mg/mL. No other Sandimmune formulations are impacted.
Sandimune is used to prevent organ rejection in kidney, liver, and heart allogeneic transplants. The drug may also be used to treat chronic rejection in patients previously treated with other immunosuppressive agents.
The formulation of crystals could result in non-uniform distribution of the cyclosporine, resulting in under-dosing or over-dosing. Under-dosing would decrease the efficacy of Sandimmune and potentially lead to graft rejection and graft loss in transplant patients. Over-dosage could lead to cyclosporine toxicity in the long term. Novartis has not received any reports of adverse events related to this recall, to date.
The affected lots are FX001500 with an expiration date of September 2024 and FX001582 with an expiration date September 2024. The lots have an NDC number of 0078-0110-22. These lots were only distributed in the United States beginning in January 2022 and September 2022, respectively.
Related: Crystal Formation in Bottles Leads to Recall of Sandimmune
This is the second recall of Sandimmune related to the formulation of crystals in some bottles. Novartis had issued a recall in September 2023 of a different lot.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More